SCHEMBL4610145

SCHEMBL4610145

CC(C)(C)OC(=O)C(Cc1ccccc1)CS(=O)(=O)Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 2/20 0.44
ITGB7 P26010 2/20 0.44
CYP1A2 P05177 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
ATM Q13315 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CTSS P25774 2/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSK P43235 1/20 0.41
CPA1 P15085 2/20 0.40
CPA3 P15088 2/20 0.40
FOLH1 Q04609 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7332197 0.84 KMT2A (0.50) CYP1A2CA12CA1CA7CA14
SCHEMBL7141356 0.83 EPHX2 (0.51) CYP1A2CPA1CPA3FOLH1CPB1
Hydrochloric Acid SCHEMBL7420885 0.82 EPHX2 (0.50) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7300596 0.81 ALDH1A1 (0.49) CYP1A2CA12CA1TDP1CA2
SCHEMBL7309732 0.81 ALDH1A1 (0.49) CYP1A2CA12CA1TDP1CA2
SCHEMBL9325914 0.81 ALDH1A1 (0.49) CYP1A2CA12CA1TDP1CA2
SCHEMBL8439144 0.81 CYP1A2 (0.55) ITGA4ITGB7CYP1A2ATMPOLB
SCHEMBL7862241 0.80 MMP13 (0.44) ITGA4ITGB7POLBCA2CA9
SCHEMBL1519838 0.80 CPA1 (0.60) ITGA4ITGB7CYP1A2ATMPOLB
SCHEMBL4610670 0.80 CYP1A2 (0.49) ITGA4ITGB7CYP1A2ATMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641771-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS UCB PHARMA SA (BE) 2008-10-15 EP disclosed
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-12-07 US disclosed
EP-1648868-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R&D LTD (GB) 2006-11-15 EP disclosed
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-10-26 US disclosed
EP-1648868-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS Celltech R & D Limited (GB) 2006-04-26 EP disclosed
EP-1641771-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS Celltech R & D Limited (GB) 2006-04-05 EP disclosed
WO-2004113298-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R & D LIMITED (GB) 2004-12-29 WO disclosed
WO-2004113312-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R & D LIMITED (GB) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD2, CD22, NEU3 ITGA4 742/4885ITGB7 1773/4885CYP1A2 3302/4885
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD22, CD2, DPP3 ITGA4 656/4885ITGB7 1450/4885CYP1A2 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.